At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.

Health Care

Life Sciences

Therapeutics

Avid Radiopharmaceuticals

Avid Radiopharmaceuticals' headquarters in Philadelphia, PA, United States

Ian Halvorsen

David Wilson

Lisaann Trembath

Kelly Conway

Amanda Morris

Marybeth Devine

Caitlin Pearson

Christine Gallagher

Luckens Osias

Anne McGeehan

Carey Horchler

Robert Morrison

Brandon Rogenmuser

Joachim Berkner

Rosemary Roebuck (Soto)

Ed Borkowski

Stephen Boyle

Lindsay Rose Duonnolo

Thomas Harris

Marcy Williams

Leah Schmall

Molly Johnson

Adam Hoye

Ximin Li

Qianwa Liang

Eric Wang

Melissa Pratt

Description

People (24)